NL
DE
31 October 2019
“Radboudumc strives for continuous improvement of patient care,” says Professor Jurgen Fütterer, intervention radiologist at Radboudumc. “Because we are involved in the development of new treatment techniques, we can tailor these techniques as closely as possible to the needs of the patient. The expansion of our cooperation with Quirem Medical fits in perfectly with that aim.”
Person-oriented treatment
The research into holmium microspheres in Radboudumc takes place in the Radiology and Nuclear Medicine department. The 'nuclear local interventions' are carried out in close cooperation with Jurgen Fütterer and other researchers at the Department of Nuclear Medicine. Fütterer: “Our special MITeC operating theatres enable us to use MRI imaging to show the location of the radioactive holmium spheres during the treatment. This allows treatment that is precisely tailored to the individual.”
Image-guided treatment
Quirem Medical, located in Deventer, is the result of previous innovations by the Nijsen research group. “We have also developed radioactive polylactic acid microspheres for the treatment of liver tumors, called radio embolization,” says Fütterer. "We are now focusing on further refining this image-guided treatment to get an even higher dose into patients' liver tumors. We are also working on similar treatments for pancreatic and brain tumors where we will also apply radiation directly to the tissues themselves. These are developing techniques that Quirem Medical, together with Radboudumc, will try to introduce to the clinic in the coming years."
Working together on innovative applications
Quirem Medical develops and produces holmium-166 microspheres for the treatment of tumors. CEO Jan Sigger: “The radioactive holmium microspheres ensure that the tumors are irradiated locally. Moreover, thanks to the holmium, we can see exactly where the microspheres are and whether there are enough microspheres surrounding the tumor. Our technology is currently being used to treat liver tumors that are no longer operable. Radboudumc offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications. The high-quality hot lab facilities in the Radboud Translational Medicine center can also help in the further development of our pipeline of innovative, new applications.”
About Quirem Medical
Quirem Medical is a growing medical device company that is developing the next generation of microspheres for targeted interventional treatment of liver tumors. Quirem Medical is based in Deventer, the Netherlands.
“Radboudumc strives for continuous improvement of patient care,” says Professor Jurgen Fütterer, intervention radiologist at Radboudumc. “Because we are involved in the development of new treatment techniques, we can tailor these techniques as closely as possible to the needs of the patient. The expansion of our cooperation with Quirem Medical fits in perfectly with that aim.”
Person-oriented treatment
The research into holmium microspheres in Radboudumc takes place in the Radiology and Nuclear Medicine department. The 'nuclear local interventions' are carried out in close cooperation with Jurgen Fütterer and other researchers at the Department of Nuclear Medicine. Fütterer: “Our special MITeC operating theatres enable us to use MRI imaging to show the location of the radioactive holmium spheres during the treatment. This allows treatment that is precisely tailored to the individual.”
Image-guided treatment
Quirem Medical, located in Deventer, is the result of previous innovations by the Nijsen research group. “We have also developed radioactive polylactic acid microspheres for the treatment of liver tumors, called radio embolization,” says Fütterer. "We are now focusing on further refining this image-guided treatment to get an even higher dose into patients' liver tumors. We are also working on similar treatments for pancreatic and brain tumors where we will also apply radiation directly to the tissues themselves. These are developing techniques that Quirem Medical, together with Radboudumc, will try to introduce to the clinic in the coming years."
Working together on innovative applications
Quirem Medical develops and produces holmium-166 microspheres for the treatment of tumors. CEO Jan Sigger: “The radioactive holmium microspheres ensure that the tumors are irradiated locally. Moreover, thanks to the holmium, we can see exactly where the microspheres are and whether there are enough microspheres surrounding the tumor. Our technology is currently being used to treat liver tumors that are no longer operable. Radboudumc offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications. The high-quality hot lab facilities in the Radboud Translational Medicine center can also help in the further development of our pipeline of innovative, new applications.”
About Quirem Medical
Quirem Medical is a growing medical device company that is developing the next generation of microspheres for targeted interventional treatment of liver tumors. Quirem Medical is based in Deventer, the Netherlands.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Mathias Prokop appointed department head of Radiology UMCG He also remains department head of Imaging Radboudumc
11 April 2022 As of May 1, Mathias Prokop will become Department Head of Radiology at UMCG. He will fulfill this role in addition to his current position as Professor and Department Head of Imaging at the Radboudumc. Jurgen Fütterer will assume the daily management of the Radboudumc clinic. read more
Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI
1 December 2021Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.
read more
KWF grant for better selection of individuals and lung nodules in lung cancer screening
1 November 2021 The Dutch Cancer Society has awarded the consortium project ‘Multi-source data approach for Personalized Outcome Prediction in lung cancer screening’ with a grant of 1,425,000 Euro. Colin Jacobs will lead the work package on using artificial intelligence for accurate risk estimation of lung nodules. read more
New start-up Patholyt will bring AI research into pathology diagnostics
21 September 2021 Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research. read more
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview
22 July 2021 Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map. read more
